Skip to Main Content
Table 2—

Hepatic lipase activity (units/l) after 30 weeks of treatment

PatientsnPlaceboAtorvastatin
10 mg80 mg
All 198    
 Baseline  406 ± 156 402 ± 152 410 ± 138 
 30 weeks  382 ± 146 361 ± 149* 313 ± 112* 
Males 107    
 Baseline  449 ± 138 429 ± 154 451 ± 143 
 30 weeks  425 ± 128 390 ± 150* 343 ± 98* 
Females 71    
 Baseline  358 ± 131 360 ± 155 356 ± 109 
 30 weeks  343 ± 125 318 ± 138* 278 ± 120* 
PatientsnPlaceboAtorvastatin
10 mg80 mg
All 198    
 Baseline  406 ± 156 402 ± 152 410 ± 138 
 30 weeks  382 ± 146 361 ± 149* 313 ± 112* 
Males 107    
 Baseline  449 ± 138 429 ± 154 451 ± 143 
 30 weeks  425 ± 128 390 ± 150* 343 ± 98* 
Females 71    
 Baseline  358 ± 131 360 ± 155 356 ± 109 
 30 weeks  343 ± 125 318 ± 138* 278 ± 120* 

Continuous data are means ± SD.

*

P < 0.001, significantly different from baseline in each treatment group.

Close Modal

or Create an Account

Close Modal
Close Modal